4.4 C
Glasgow
Wednesday, February 11, 2026
spot_img

More News

Skin damage protein ID could lead to new therapies

Jim Cornall -
Radiotherapy is one of the main treatment forms for cancer. Among its most common side effects is skin damage,...

Origami Therapeutics and Ipsen to advance protein degrader programme

Jim Cornall -
Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, has announced...

IQVIA and Boehringer Ingelheim announce data collaboration

Jim Cornall -
IQVIA has announced a strategic long-term collaboration with Boehringer Ingelheim. Boehringer Ingelheim has selected IQVIA’s Data-as-a-Service (DaaS+) technology offering...

Next-generation biopreservation for cell therapy

Jim Cornall -
CaseBioscience has launched CaseCryo CTG DMSO, a next-generation cryopreservation solution developed to support clinical cell therapy development, at Advanced...

Predicting cancer evolution

Jim Cornall -
Predicting tumour progression is one of the major challenges in oncology. Scientists at the University of Geneva (UNIGE) and...

Base to Base biotech podcast 45: Chronic pain, urology, Affibody molecules and radioligand therapy

Jim Cornall -
This week, we chat with Affibody CEO David Bejker, and Martin Gleave, founder and chief medical officer at Sustained...

Johnson & Johnson prostate cancer drug receives CHMP positive opinion

Jim Cornall -
Johnson & Johnson has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...

Breakthru Medicine emerges from stealth to develop cancer drugs

Jim Cornall -
Breakthru Medicine has emerges from stealth with the close of a $60m Series A financing round following a prior...

FDA Rare Pediatric Disease designation for mucopolysaccharidosis Type II treatment

Jim Cornall -
Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, has announced that the U.S. Food and...

CIRM approves $100m plan to accelerate genetic therapies for patients with rare diseases

Jim Cornall -
The California Institute for Regenerative Medicine (CIRM) has approved a new funding programme to accelerate therapies for rare diseases,...

Researchers develop more reliable platform to test antibody medicines

Jim Cornall -
An international research consortium, led by scientists at VIB and UGent in Belgium, has developed a new platform that...

Positive topline results from acne study

Jim Cornall -
Ascletis Pharma Inc. has announced positive topline results from its phase III open-label study evaluating denifanstat (ASC40), a first-in-class,...

Sarbecovirus vaccine trial starts

Jim Cornall -
SK bioscience has announced the initiation of a global phase 1/2 clinical trial in Australia for GBP511, a vaccine...

Vetter Pharma to build new manufacturing site in Germany

Jim Cornall -
German CDMO Vetter has confirmed its plans to build a production facility in the Saarland region of southwest Germany. Construction...

New dementia treatment strategy proposed

Jim Cornall -
Conventional treatments of Alzheimer’s disease, one of the most common forms of dementia, have been largely focused on targeting...

FDA IND clearance for Trace Biosciences’ nerve-specific imaging agent

Jim Cornall -
Trace Biosciences, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug...

Lilly injectable medicine and device manufacturing facility to be built in Pennsylvania

Jim Cornall -
Eli Lilly and Company has announced plans to invest more than $3.5bn in a new manufacturing facility in the...

A broken DNA repair tool accelerates aging

Jim Cornall -
Although DNA is tightly packed and protected within the cell nucleus, it is constantly threatened by damage from normal...

Base to Base biotech podcast 44: Treating breast cancer and how a CDMO and immuno-oncology company collaborate

Jim Cornall -
This week, we chat with Pan Cancer T CEO Dr. Rachel Abbott, about – among other things – triple-negative...

Two-faced nanoparticles help antibiotics treat resistant bacteria

Jim Cornall -
In the global battle against antimicrobial resistance (AMR), an international research team has unveiled what it says is a...

Resolve M Therapeutics exits from stealth

Jim Cornall -
Resolve M Therapeutics, Inc. has announced its exit from stealth. Resolve M was created through a strategic collaboration between...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media